apexian pharmaceuticals

Mark R. Kelley, Apexian Pharmaceuticals chief scientific officer, is the Betty and Earl Herr Chair in Pediatric Oncology Research and a professor in the Department of Biochemistry and Molecular Biology and the El informe de investigacin incluye segmentos especficos por regin (pas), por fabricantes, por Tipo y por Aplicacin. Apexian Pharmaceuticalss official website is www.apexianpharma.com Whalewisdom has at least 1 13G filings The firm last filed a Form D notice of exempt offering of securities on 2019-03-25. Start Free Trial . 39,451 Total Employees. Phone Number (317) 684-9106 Apex Therapeutics is an emerging clinical-stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided a unique insight into this novel biological target. Apexian Pharmaceuticals Preclinical Studies With APX3330 Shut Down Inflammatory Signaling in Leukemia. A group of medical researchers, many of whom are Eli Lilly refugees with powerful pharmaceutical experience, share a common goal of wiping out cancer. Career opportunities are published only Apexian Pharmaceuticals serves patients in the State of Indiana. INDIANAPOLIS--(BUSINESS WIRE)-- Apexian Pharmaceuticals, Inc., an Indiana-based clinical stage biotechnology company developing novel compounds to treat cancer, announced today that they are closing their Series A round.This financing follows previous investments as well as numerous grants and awards by the company since its founding. Biography Steve, who was named CEO in 2016, was previously Chief Executive Officer and President of Cornerstone Pharmaceuticals, an oncology discovery and development company focused on cancer metabolism. Get Apexian Pharmaceuticals rKaufman & Lynd reviews, rating, hours, phone number, directions and more. Inflammation also plays a role. -Regenacy Pharmaceuticals-MAKScientific LLC-Metys Pharmaceuticals AG-Nemus Bioscience Inc-PledPharma-Sova Pharmaceuticals Inc-DermaXon LLC-Kineta Inc-Krenitsky Pharmaceuticals Inc-PeriphaGen-Apexian Pharma Apexian Pharmaceuticals is a clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose work on the APE1/Ref-1 protein has provided unique insight into this important biological target. Proceeds will be used to initiate a phase 1 clinical study for the company's lead molecule, APX3330, a novel first-in-class oral treatment for patients with cancer. Apexian Pharmaceuticals United States of America. We are innovators, leaders, and collaborators. Genetic mutations by themselves are rarely enough to Current Portfolio Companies Apexian Pharmaceuticals, Inc. Apexian Pharmaceuticals is an emerging clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose groundbreaking work on APE1/Ref-1 redox protein signaling at the Indiana University School of Medicine has provided unique insight into this important biological target. It focuses on inflammatory disorders and tumorigenesis, including cancers of the colon, pancreas, skin, blood, diabetic macular edema. The company's filing status is listed as Active and its File Number is 2008043000664. Find useful insights on Apexian Pharmaceuticalss employee, technology stack, location, news alerts and more at Slintel. Start Free Trial . This represents 7.136 percent ownership of the company. Neurological Disorders $33B+ Gene Therapy $24B+ Autoimmune Disease $30B+ Metabolic Disorders $18B+ Clinical Dashboards. Pricing. 20 North Meridian Street Indianapolis Indiana 46204 There are no jobs right now, but check back soon as we update jobs daily. Company officials announced that the U.S. Food and Drug Administration has agreed that APX3330, the As President, CEO, he built the company to be a unique discovery engine with multiple projects at the IND-enabling stage. GHO Capital. Products. Kliniske forsg for segraves, r., t., m.d., ph.d.. Kliniske forsgsregister. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Alexion Pharmaceuticals, Inc. 3w.

Get Apexian Pharmaceuticals can be contacted at (844) 463-3330. Resources. Products. The latest litigation news involving the company Apexian Pharmaceuticals Inc. () Posted October 30, 2021 by Ryan Piurek. Hi, were Apexian Pharmaceuticals. Apexian Pharmaceuticals Inc., a biotechnology company focused on developing novel compounds to treat cancer, has licensed all available patented and patent-pending technology discovered in Mark R. Kelley's laboratory at the Indiana University School of Medicine. Apexian Pharmaceuticals is Drug Discovery in United States that focus on related macular degeneration business. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. Explore Apexian Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! IBJ.com Apexian Pharmaceuticals news. Solutions. It offers pharmaceutical products for the treatment of pancreatic cancer, blood cancer, brain tumors, ovarian cancer, age-related macular degeneration, and diabetic retinopathy. Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs. Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. Solutions. Resources. Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. Leadership: Apexian Pharmaceuticals. Tamao del mercado global Tratamiento de neuropata perifrica inducida por quimioterapia 2022 Investigacin por oportunidades comerciales, participacin en la industria, tasa de crecimiento, anlisis regional, fabricacin superior como Lanzatech, Yancheng Hongtai Bioengineering, Yancheng Huade Biological y pronstico para 2028 The Company focuses in developing novel compounds to treat cancer including tumors of Apexian Pharmaceuticals is a biotechnology company that provides medicines for cancer. Apexians research is grounded and driven by the belief that better is On January 24, 2018 Apexian Pharmaceuticals, a clinical-stage biopharmaceutical company, has reported the opening of a clinical trial for patients with advanced solid tumors (Press release, Apexian Pharmaceuticals, JAN 24, 2018, View Source [SID1234523543]). SBI Capital Markets. To learn more about Apexian Pharmaceuticals, please visit the company's website at www.ApexianPharma.com Contacts Apexian Pharmaceuticals Roger Miller, 844-463-3330 x113 Email: PR@Apexianpharma.com Congratulations to Indianapolis-based Apexian Pharmaceuticals, a clinical-stage biotech company that is developing novel compounds to treat cancer. 20 North Meridian Street Indianapolis Indiana 46204 There are no jobs right now, but check back soon as we update jobs daily. Resources. 194 Pharmaceutical jobs available in American Fork, UT on Indeed.com. Public relations and investor relations professionals rely on Business Wire for Find jobs at Apexian Pharmaceuticals. Apex Therapeutics develops and commercializes pharmaceuticals for the treatment of cancer and ocular diseases. Apexian Pharmaceuticals is a clinical stage biotechnology company founded on the scientific discoveries of Dr. Mark R. Kelley, whose work on the APE1/Ref-1 protein has provided unique insight into this important biological target. Dublin, June 14, 2022 (GLOBE NEWSWIRE) -- The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.. Search Crunchbase. Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexians Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all Apexian Pharmaceuticals has raised a total of $6.9M in funding over 8 rounds. Where We Are. Apexian Pharmaceuticals is funded by 3 investors. Weekly Paper. Search Crunchbase. Berlin (Germany) Der Behandlung der durch Chemotherapie induzierten peripheren Neuropathie-Marktforschungsbericht enthlt eine detaillierte Analyse, die auf grndlichen Untersuchungen des Gesamtmarkts basiert, insbesondere zu Fragen, die an die Marktgre, das Wachstumsszenario, die potenziellen Chancen, die Betriebslandschaft, die Centro de Investigacion Sanitaria; Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri; Centro Studi Internazionali, Italy; Cervical Artery Dissections and Ischemic Stroke Patients On Aug 31, 2021 Apexian Pharmaceuticals closed a Venture Series Unknown round and raised $100,000 from IU Ventures, featuring lead investors IU Ventures. Apexian Pharmaceuticals Presents Findings at ASH Meeting Demonstrating APX3330 Impact on Inflammation and Leukemia in Preclinical Models Published: Dec 12, 2018 INDIANAPOLIS--( BUSINESS WIRE )-- Apexian Pharmaceuticals, is shedding light on the question of how pre-leukemic cells transform into full-blown leukemia. Apexian Pharmaceuticals, Inc. ownership in OCUP / Ocuphire Pharma Inc 2021-03-26 - Apexian Pharmaceuticals, Inc. has filed an SC 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 779,993 shares of Ocuphire Pharma Inc (US:OCUP). Digital Edition; Purchase Past Issues They have now developed a drug that targets this protein and is in Apexian Pharmaceuticals corporate office is located in 20 N. Meridian, Ste 801, Indianapolis, Indiana, United States and has 5 employees. Previously, Roberta was a Director, R egulatory Affairs at The Medicines and also held positions at Novartis, Pearl Pathways, Targanta Therapeutics, Eli Lilly. Eversana. Apexian Pharmaceuticals is a patient-centered biotechnology company dedicated to developing novel anti-cancer compounds that target the multiple functions of the APE1 protein. Tag: Apexian Pharmaceuticals Connecting capital to ideas and collaborating to ignite Indianas entrepreneurial ecosystem. Apexian Pharmaceuticals is currently hiring for a range of positions Our lead drug candidate APX3330 targets the APE1/Ref-1 redox protein, a molecule found in many cancers, including tumors of the colon, lung, breast, pancreas and others. Explore Apexian Pharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here! Popular Searches Apexian Pharmaceuticals Inc Apexian Pharmaceuticals Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the Apexian Pharmaceuticalss headquarters are in 20 N. Meridian, Ste 801, Indianapolis, Indiana, 46204, United States What is Apexian Pharmaceuticalss phone number? Chrome Extension. Apexian Pharmaceuticals. Company Description: Apexian Pharmaceuticals, Inc. is located in Indianapolis, IN, United States and is part of the Scientific Research and Development Services Industry. Apexian Pharmaceuticals, Inc. has 4 total employees across all of its locations and generates $268,176 in sales (USD). Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. DUBLIN--(BUSINESS WIRE)--The "Global Ophthalmics Partnering 2014-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.. Roberta Smithey is a Director, Regulatory Affairs at Apexian Pharmaceuticals based in Indianapolis, Indiana. Apexian Pharmaceuticals, Inc. discovers, develops and commercializes novel pharmaceuticals products. Where We Are. - Indianapolis, Indiana-based cancer therapeutics developer Apexian Pharmaceuticals is closing its series A financing round, the company said. Hi, were Apexian Pharmaceuticals. Consulting or Advisory Role: Apexian Pharmaceuticals, Ocuphire Pharma. Genetic mutations by themselves are rarely enough to flip the switch. BLP Management. Find jobs at Apexian Pharmaceuticals. Apexian Pharmaceuticals, a clinical-stage biotechnology company focused on developing safe and effective therapy for patients with high unmet medical needs, is pleased to announce that its Chief Scientific Officer, Mark Kelley, PhD, was recognized as an outstanding scholar and researcher during the annual IUPUI Chancellor's Academic Honors Convocation

apexian pharmaceuticals

apexian pharmaceuticalsÉcrit par